Polaryx closes $10M PIPE at ~$4.00/share to fund Phase 2 SOTERIA basket trial

Polaryx Therapeutics, Inc.

Private placement of 2,502,696 common shares at avg $4.00/share for $10M gross proceeds to ~35 investors.
Largest stockholder MStone Partners Healthcare purchased 88,453 shares ($360k) in the offering.
Net proceeds will fund initiation of Phase 2 SOTERIA trial (CLN2, CLN3, Krabbe, Sandhoff) and extend cash runway through Q2 2027.
No resale registration statement will be filed; shares issued under Section 4(a)(2) and Regulation S exemption.
FDA Fast Track Designation already in place for all four planned LSD indications.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Polaryx Therapeutics, Inc. issued 2,502,696 shares of common stock to approximately 35 investors, including existing investors for aggregate gross proceeds of $10 million.

Security: common stock
Shares: 2,502,696 shares
Purchaser: approximately 35 investors, including existing investors
Consideration: aggregate gross proceeds of $10 million

Exact text from the filing

On May 27, 2026, Polaryx Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with approximately 35 investors, including existing investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement a total of 2,502,696 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Private Placement”), representing approximately 5.3% of the Company’s outstanding shares immediately prior to the Private Placement, for aggregate gross proceeds of $10 million.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Polaryx Therapeutics, Inc. entered into Securities Purchase Agreement with approximately 35 investors, including existing investors (the "Purchasers") valued at $10 million (effective 2026-05-27).

Action: entry
Agreement: equity purchase
Counterparty: approximately 35 investors, including existing investors (the "Purchasers")
Value: $10 million
Effective: 2026-05-27

Exact text from the filing

On May 27, 2026, Polaryx Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with approximately 35 investors, including existing investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement a total of 2,502,696 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Private Placement”), representing approximately 5.3% of the Company’s outstanding shares immediately prior to the Private Placement, for aggregate gross proceeds of $10 million.

View on SEC.gov

Browse all equity issuances →

Polaryx Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-062155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.